Skip to main content

Drug Interactions between depo-subQ provera 104 and morphine liposomal

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Minor

medroxyPROGESTERone morphine liposomal

Applies to: depo-subQ provera 104 (medroxyprogesterone) and morphine liposomal

Oral contraceptives induce glucuronidation and may decrease plasma concentrations of morphine, diamorphine, and other opioids. Oral contraceptives may influence opioid analgesic effects and opioid dosage may need to be adjusted. However, the clinical significance of this interaction has not been established.

References (5)
  1. Shenfield GM, Griffin JM (1991) "Clinical pharmacokinetics of contraceptive steroids: an update." Clin Pharmacokinet, 20, p. 15-37
  2. (2001) "Product Information. NuvaRing (ethinyl estradiol-etonogestrel)." Organon
  3. Cerner Multum, Inc. (2015) "Canadian Product Information."
  4. (2022) "Product Information. VyLibra (ethinyl estradiol-norgestimate)." Afaxys Inc.
  5. Ribeiro-Dasilva MC, Shinal RM, Glover T, Williams RS, Staud R, Riley JL 3rd, Fillingim RB (2011) "Evaluation of menstrual cycle effects on morphine and pentazocine analgesia" Pain, 152, p. 614-622

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer